Table 1—

Effects of ambroxol on trypsin-like protease activity, pulmonary surfactant (SP-A) and mucus protease inhibitor (MPI) in bronchoalveolar lavage fluid of mice infected with influenza-A virus

Regulatory factorDose of ambroxol mg·kg−1·day−1Days after virus infection
01234567
Trypsin-like protease activity µU·mL−1025.0±10.038.4±2.970.0±8.899.0±28.3125.0±2.9146.8±21.0160.0±21.0124.0±30.0
1056.0±2.3*81.0±10.0135.0±17.0156.6±25.0201.5±20.0*172.0±30.0175.0±26.0
3060.0±10.0*90.0±12,5129.0±33.7221.5±38.0*148.0±19.8137.5±17.053.0±15.0*
SP-A ng·mL−102.1±0.62.3±0.16.0±2.18.6±3.29.2±4.610.4±2.212.5±1.57.3±1.9
109.4±3.9*14.5±2.6*14.8±2.915.6±3.419.1±3.5*16.5±3.115.1±3.1*
3011.3±1.1*14.5±3.3*16.0±5.121.1±6.0*12.4±1.212.1±1.74.9±4.9
MPI µU·mL−10110.0±56.0123.0±25.0188.6±61.0256.0±71.4360.0±97.0425.0±120.0483.0±69.0329.0±81.0
10200.0±20.0*396.7±62.6*480.0±120.0*587.6±147.0*933.0±170.0*600.0±98.0660.0±180.0*
30305.0±18.3*518.3±183.0*753.0±216.0*929.0±95.0*800.0±134.0*500.0±61.0156.0±30.0*
  • The data are presented as means±sd unless otherwise stated. (n=5) at each time point

  • *: p<0.05 between control and ambroxol